Related Experiment Videos
Trial of ketotifen in childhood asthma
1Institute of Child Health, J. J. Group of Government Hospitals, Bombay.
Insights
Ketotifen showed potential benefits for children with asthma, particularly those with shorter disease duration and on limited regular medication. Further research is needed to confirm efficacy in pediatric asthma management.
Area of Science:
- Pediatric Pulmonology
- Clinical Pharmacology
Background:
- Asthma is a chronic respiratory disease affecting children worldwide.
- Effective management strategies for pediatric asthma are crucial.
Purpose of the Study:
- To evaluate the efficacy of Ketotifen in children with asthma.
- To identify patient subgroups that may benefit from Ketotifen treatment.
Main Methods:
- An open-label trial involving 29 children with asthma.
- Oral administration of Ketotifen at 1 mg twice daily.
- Weekly follow-up for 3 months.
Main Results:
- Ketotifen showed non-statistically significant benefits in children with asthma duration less than 2 years on regular or occasional treatment.
- Marginal effects were observed in children irregularly taking salbutamol and theophylline concurrently.
- No benefit was noted in children receiving prednisolone.
Conclusions:
- Ketotifen may offer some benefit in specific pediatric asthma populations.
- Treatment response appears dependent on asthma duration and concomitant medication regimens.
- Further controlled studies are warranted to validate these findings.
Abstract:
An open trial of Ketotifen was conducted on 29 children suffering from asthma of varying duration. The drug was given orally in a dose of 1 mg twice a day. Children were followed up weekly for a period of 3 months. It was found beneficial (though the benefit was not statistically significant) in children having asthma of less than 2 years duration who were taking one drug regularly or were on occasional treatment. There was marginal effect in children taking salbutamol and theophylline together, but irregularly and no benefit in children taking prednisolone.